WASHINGTON, Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of t ...

Danaher Corporation (DHR) has been benefiting from strength in its Diagnostics segment and accretive acquisitions. The company's measures to reward its shareholders are encouraging. Let's discuss the factors that should influence investors to retain this Zacks Rank #3 (Hold) company for the time being. Growth Catalysts of DHR Business Strength: Strength in Danaher's clinical diagnostics business, driven by growth in Leica Biosystems and Beckman Colter Diagnostics units, has been supporting the Diagnostics s ...

WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines.  For both the third quarter and full year 2024, the Company continues ...

WASHINGTON, Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery, Executive Vice President, Diagnostics. A link to the webcast and accompanying slide presentation will be available on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentatio ...

PM Images Introduction A blended P/E ratio of 36x. 0% EPS growth in 2024. I think it's fair to say that this does not look like a winning combination. Especially in light of what I wrote in a recent article titled "Buying Wonderful Businesses At Fair Prices - The Billionaire Way," it may be weird that I give you a stock with a lofty valuation and no expected growth in 2024. One of the "Buffett-style" checklist items was to make sure we buy companies trading at a discount. [...] do you fully understand the ...

It has been about a month since the last earnings report for Danaher (DHR) . Shares have added about 2% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Danaher Q2 Earnings Beat, Biotechnology Sales Dip Y/YD ...

NSA Digital Archive/E+ via Getty Images Introduction It's time to talk big-picture stuff. However, before I get to the main message, I wanted to share a chart I just came across. As we are currently in a very volatile pre-election period with a load of political uncertainty, Ritholz Wealth Management produced a chart that shows the S&P 500 returns during presidential terms - including the max drawdown. Ritholz Asset Management One thing clearly becomes obvious: (almost) every single president has gone t ...

Danaher Corporation’s (DHR) second-quarter 2024 adjusted earnings (excluding 50 cents from non-recurring items) of $1.72 per share surpassed the Zacks Consensus Estimate of $1.57. The bottom line declined 0.6% year over year.Danaher’s net sales of $5.7 billion outperformed the consensus estimate of $5.6 billion. However, the metric declined 3% year over year due to lower core sales in the Biotechnology segment.Organic sales decreased 3.5%. Acquisitions had a positive impact of 2% on quarterly sales while ad ...

Key TakeawaysDanaher's second-quarter results beat analysts' expectations on both profit and revenue.CEO Rainer Blair cited "positive momentum" in Danaher's bioprocessing business and "strong performance" in molecular testing subsidiary Cepheid.Danaher affirmed its guidance that non-GAAP core revenue will decline by a low-single-digit percentage year-over-year. Danaher Corp. (DHR) beat analysts' expectations on the top and bottom lines with its second-quarter results, sending shares higher in intraday tradi ...

The biotechnology, diagnostics, and life sciences company looks set to return to its long-term growth rate.Danaher's (DHR 7.12%) core revenue decline of 3.5% in the second quarter might not seem like anything to write home about. Still, as ever in investing, it's about context, and the company's earnings report shows that it's set to return to its long-term growth track.The good news encouraged investors to bid the stock up by more than 7% in trading before 10 a.m. ET today.Danaher beats guidanceAs you migh ...